FDA
-
-
-
-
-
-
-
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
TRACON Pharmaceutical (TCON) Announces Arbitration Award in Dispute with I-Mab (IMAB)
-
-
-
-
-
-
-
TRACON Pharmaceutical (TCON) Announces Independent Data Monitoring Committee Recommends ENVASARC Phase 2 Trial to Proceed as Planned
-
-
-
-
-
-
-
TRACON Pharmaceutical (TCON) Granted FDA Approval of IND for CTLA-4 Antibody YH001
-
-
-
-
-
-
-
TRACON Pharmaceutical (TCON) Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
-
-
-
-
-
-
-
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
-
-
-
-
-
-
-
TRACON Pharmaceutical (TCON) Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma
-
251,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All